Selected article for: "point mutant and related mutant"

Author: Aravinth Kumar Jayabalan; Diane E. Griffin; Anthony K. L. Leung
Title: Alphavirus nsP3 ADP-ribosylhydrolase Activity Disrupts Stress Granule Formation
  • Document date: 2019_6_20
  • ID: n8sjpcbs_28
    Snippet: Formation of aberrant SGs is a hallmark of several neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) [1, 57] . Genetic mutations are commonly observed in RNA-binding proteins such as FUS (e.g. R495X), and overexpression of some ALS-related mutant RNA-binding proteins results in the formation of aggregates enriched in canonical SG components such as G3BP1 and translation initiation factors [.....
    Document: Formation of aberrant SGs is a hallmark of several neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) [1, 57] . Genetic mutations are commonly observed in RNA-binding proteins such as FUS (e.g. R495X), and overexpression of some ALS-related mutant RNA-binding proteins results in the formation of aggregates enriched in canonical SG components such as G3BP1 and translation initiation factors [58, 59] . We hypothesized that the formation of FUS R495X-mediated SG-like aggregates might also be suppressed by nsP3 ADPribosylhydrolase activity. We co-transfected FLAG-tagged FUS R495X with either GFP alone, GFPtagged nsP3 WT or GFP-nsP3 G32E into U2OS cells and examined the presence of FUS R495Xinduced aggregates. Consistent with previous reports [48, 49, 60] , overexpression of FUS-R495X itself formed SG-like aggregates, which were positive for G3BP1 and eIF3b, in ~50% of transfected cells (vector, Fig. 3c , e, data not shown). Intriguingly, co-transfection with full-length nsP3 WT, but not the point mutant G32E, decreased formation of these aggregates by two-fold (Fig. 3c, e) . Moreover, the All rights reserved. No reuse allowed without permission.

    Search related documents:
    Co phrase search for related documents
    • aggregate formation and frontotemporal dementia: 1
    • aggregate formation and lateral sclerosis: 1
    • aggregate formation and neurodegenerative disease: 1, 2, 3, 4
    • ALS amyotrophic lateral sclerosis and amyotrophic lateral sclerosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ALS amyotrophic lateral sclerosis and frontotemporal dementia: 1, 2
    • ALS amyotrophic lateral sclerosis and FTD frontotemporal dementia: 1, 2
    • ALS amyotrophic lateral sclerosis and lateral sclerosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ALS amyotrophic lateral sclerosis and neurodegenerative disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • amyotrophic lateral sclerosis and frontotemporal dementia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • amyotrophic lateral sclerosis and FTD frontotemporal dementia: 1, 2, 3
    • amyotrophic lateral sclerosis and lateral sclerosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • amyotrophic lateral sclerosis and neurodegenerative disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • frontotemporal dementia and FTD frontotemporal dementia: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • frontotemporal dementia and lateral sclerosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • frontotemporal dementia and neurodegenerative disease: 1, 2, 3, 4, 5, 6, 7, 8
    • FTD frontotemporal dementia and lateral sclerosis: 1, 2, 3
    • FTD frontotemporal dementia and neurodegenerative disease: 1, 2
    • genetic mutation and rna bind: 1
    • genetic mutation and rna bind protein: 1